LiRIS Placebo

OTHER4 trials

Sponsors

Allergan

Conditions

Cystitis, InterstitialInterstitial CystitisPainful Bladder SyndromeUlcer

Phase 2

Double-Blind Placebo Controlled Study of Safety,Tolerability, and Efficacy of LiRIS® in Women With Interstitial Cystitis

TerminatedNCT01475253

AllerganInterstitial Cystitis

Start: 2011-11-30End: 2012-12-31Updated: 2015-09-21

Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis

TerminatedNCT01824303

AllerganInterstitial Cystitis

Start: 2013-03-31End: 2014-12-31Updated: 2016-01-26

A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions

CompletedNCT02395042

AllerganCystitis, Interstitial, Ulcer

Start: 2015-04-15End: 2017-11-20Updated: 2018-10-05

A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome

CompletedNCT02411110

AllerganCystitis, Interstitial, Painful Bladder Syndrome

Start: 2015-05-21End: 2017-01-09Updated: 2018-01-04

Related Papers

Safety, tolerability, and efficacy of LiRIS 400 mg in women with interstitial cystitis/bladder pain syndrome with or without Hunner lesions

Neurourology and Urodynamics2021-07-2012 citations